Lauren White
Fortuna: 121 909 $ al 31/05/2026
Fortuna: 121 909 $ al 31/05/2026
Lauren A. White is currently Chief Financial Officer at Seaport Therapeutics, Inc. since 2024.
Former roles include Chief Financial Officer & Senior Vice President at ImmunoGen, Inc. from 2023 to 2024, Treasurer, Chief Financial & Accounting Officer at C4 Therapeutics, Inc. from 2021 to 2023, and VP, Global Head-Business Planning & Analysis at Novartis Institutes for Biomedical Research, Inc. Education includes an MBA from Harvard Business School conferred in 2007 and an undergraduate degree from Wallace E Carroll School of Management conferred in 2000.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
0,01 % | 04/05/2026 | 6.702 ( 0,01 % ) | 121 909 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|
| Empresas | Cargo | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Director Financiero/CFO | 01/01/2024 |
| C4 THERAPEUTICS, INC. | Director Financiero/CFO | 15/09/2023 |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wallace E Carroll School of Management
Wallace E Carroll School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.